Objective The multinational ERYTHRO ( NCT06046534) study investigated the experience of patients with moderate-to-severe SLE ...
A retrospective study compared cardiovascular risks among patients with SLE who did and did not develop lupus nephritis and/or antiphospholipid antibody-positivity over time.
Lupus nephritis has a high burden of kidney and non-kidney damage accrual due to persistent disease activity, treatment-related toxicity, and age-related factors.
Real-world evidence supports belimumab’s safety over 5 years for longer-term SLE management. Belimumab added to standard of care (SOC) therapy shows comparable 5-year safety to SOC therapy alone in ...
Lupus Affects Black Children Differently. Here’s What Parents Should Know About Symptoms & Treatment
Erin Johnson was in middle school when she began experiencing severe exhaustion, joint pain, and skin rashes. She initially thought it was due to over-practicing as a member of the drill team. “My ...
A systematic review through November 2025 (PubMed, Web of Science, Scopus, ScienceDirect) identified 27 eligible studies evaluating azathioprine exposure and posttransplant skin cancer risk. Pooled ...
Lupus is enigmatic. It can be both mild and severe, visible and hidden, and most importantly, misdiagnosed. That complexity makes it hard to detect and treat — and even harder to track. Reports ...
Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon Therapeutics in 2023, hit the primary endpoint in a phase 2 trial for discoid lupus ...
US FDA rejects AstraZeneca's subcutaneous Saphnelo AstraZeneca to keep working with FDA on application Shares in AstraZeneca fall by more than 1.5% Feb 3 (Reuters) - AstraZeneca (AZN.L), opens new tab ...
Add Yahoo as a preferred source to see more of our stories on Google. A company logo is seen at the AstraZeneca site in Macclesfield, Britain, May 11, 2021. REUTERS/Phil Noble Feb 3 (Reuters) - ...
Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the self-administered drug formulation in lupus patients with a positive phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results